NRP-1 expression is strongly associated with the progression of pituitary adenomas

Lee,Sang  Won; Lee,Jung  Eun; Yoo,Chang  Young; Ko,Myoung  Seok; Park,Chan  Soon; Yang,Seung-Ho

doi:10.3892/or.2014.3392

NRP-1 expression is strongly associated with the progression of pituitary adenomas

Authors:
- Sang Won Lee
- Jung Eun Lee
- Chang Young Yoo
- Myoung Seok Ko
- Chan Soon Park
- Seung-Ho Yang
View Affiliations

Affiliations: Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Paldal-gu, Suwon 442-723, Republic of Korea, Department of Pathology, St. Vincent's Hospital, The Catholic University of Korea, Paldal-gu, Suwon 442-723, Republic of Korea, Asan Institute for Life Sciences, Asan Medical Center, Seoul 138-736, Republic of Korea, Department of Otolaryngology, St. Vincent's Hospital, The Catholic University of Korea, Paldal-gu, Suwon 442-723, Republic of Korea
Published online on: August 7, 2014 https://doi.org/10.3892/or.2014.3392
Pages: 1537-1542

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to identify a predictive marker associated with tumor progression or recurrence. We investigated the expression of p53, Ki-67, Bax, Bcl-2, vascular endothelial growth factor (VEGF)-A, VEGFR-1, VEGFR-2 and neuropilin-1 (NRP-1) in pituitary adenomas (PAs) with/without tumor progression during follow-up periods. We compared the expression of these molecules in primary and recurrent specimens to identify a predictive marker associated with tumor progression. Nineteen patients had no progression for more than 5-years of follow-up. Nine patients had tumor progression within 5 years of their first transsphenoidal surgery (TSS) surgery and underwent re-TSS for treating progression of adenoma. Tumor size was larger and involvement of the cavernous sinus was more frequent in the progression group than these variables in the no progression group. A strong association was observed between NRP-1 expression and tumor progression. No significant risk for developing tumor progression was associated with Ki-67, p53, Bax, Bcl-2, VEGFR-1, VEGFR-2, or VEGF-A expression. Four of nine patients showed strong NRP-1 immunoreactivity in progression specimens. Negative NRP-1 immunoreactivity in the initial specimens was converted into strong positivity in the progression specimens of five patients. NRP-1 could be a relevant PA marker of progression and could be a potential target for medical therapy.

View Figures

View References

1	Ezzat S, Asa SL, Couldwell WT, et al: The prevalence of pituitary adenomas: a systematic review. Cancer. 101:613–619. 2004. View Article : Google Scholar : PubMed/NCBI
2	Hsu DW, Hakim F, Biller BM, et al: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 78:753–761. 1993. View Article : Google Scholar : PubMed/NCBI
3	Gejman R, Swearingen B and Hedley-Whyte ET: Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol. 39:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
4	Lloyd RV: Pituitary tumors. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Endocrine Organs. DeLellis A: IARC Press; Lyon: pp. 10–13. 2004
5	Hentschel SJ, McCutcheon lE, Moore W and Durity FA: P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 30:215–219. 2003. View Article : Google Scholar : PubMed/NCBI
6	Sambaziotis D, Kapranos N and Kontogeorgos G: Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas. Pituitary. 6:127–133. 2003. View Article : Google Scholar : PubMed/NCBI
7	Iuchi T, Saeki N, Osato K and Yamaura A: Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir. 142:1345–1351. 2000. View Article : Google Scholar
8	Cohen AB and Lessell S: Angiogenesis and pituitary tumors. Semin Ophthalmol. 24:185–189. 2009. View Article : Google Scholar : PubMed/NCBI
9	Tammela T, Enholm B, Alitalo K and Paavonen K: The biology of vascular endothelial growth factors. Cardiovasc Res. 65:550–563. 2005. View Article : Google Scholar : PubMed/NCBI
10	Oh H, Takagi H, Otani A, et al: Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA. 99:383–388. 2002. View Article : Google Scholar : PubMed/NCBI
11	Benveniste RJ, King WA, Walsh J, et al: Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 102:1004–1012. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 13:1893–1903. 1995.PubMed/NCBI
13	Thunnissen FB, Schuurbiers OC and den Bakker MA: A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology. 48:779–786. 2006. View Article : Google Scholar : PubMed/NCBI
14	Bielenberg DR, Pettaway CA, Takashima S and Klagsbrun M: Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res. 312:584–593. 2006. View Article : Google Scholar : PubMed/NCBI
15	Guttmann-Raviv N, Kessler O, Shraga-Heled N, et al: The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 231:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
16	Turner HE, Nagy Z, Gatter KC, et al: Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab. 85:1159–1162. 2000. View Article : Google Scholar : PubMed/NCBI
17	Di Ieva A, Grizzi F, Ceva-Grimaldi G, et al: Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J Anat. 211:673–680. 2007.PubMed/NCBI
18	Takada K, Yamada S and Teramoto A: Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr Pathol. 15:131–139. 2004. View Article : Google Scholar : PubMed/NCBI
19	Fukui S, Nawashiro H, Otani N, et al: Vascular endothelial growth factor expression in pituitary adenomas. Acta Neurochir Suppl. 86:519–521. 2003.PubMed/NCBI
20	Fukui S, Otani N, Nawashiro H, et al: The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J Clin Neurosci. 10:320–324. 2003. View Article : Google Scholar : PubMed/NCBI
21	Sánchez-Ortiga R, Sánchez-Tejada L, Moreno-Perez O, et al: Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary. 16:370–377. 2013.PubMed/NCBI
22	Onofri C, Theodoropoulou M, Losa M, et al: Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol. 191:249–261. 2006. View Article : Google Scholar
23	Cristina C, Perez-Millan MI, Luque G, et al: VEGF and CD31 association in pituitary adenomas. Endocr Pathol. 21:154–160. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nör JE, Christensen J, Mooney DJ and Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 154:375–384. 1999.PubMed/NCBI
25	Turner HE, Nagy Z, Gatter KC, Esiri MM, et al: Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer. 82:1441–1445. 2000. View Article : Google Scholar : PubMed/NCBI
26	Pan Q, Chanthery Y, Liang WC, et al: Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67. 2007. View Article : Google Scholar : PubMed/NCBI
27	Banerjee SK, Zoubine MN, Tran TM, et al: Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. Int J Oncol. 16:253–260. 2000.PubMed/NCBI
28	Pan Q, Chathery Y, Wu Y, et al: Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 282:24049–24056. 2007. View Article : Google Scholar : PubMed/NCBI
29	Fu L, Kitamura T, Iwabuchi K, Ichinose S, et al: Interplay of neuropilin-1 and semaphorin 3A after partial hepatectomy in rats. World J Gastroenterol. 18:5034–5041. 2012. View Article : Google Scholar : PubMed/NCBI
30	Matthies AM, Low QE, Lingen MW and DiPietro LA: Neuropilin-1 participates in wound angiogenesis. Am J Pathol. 160:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
31	Brusselmans K, Bono F, Collen D, et al: A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem. 280:3493–3499. 2005. View Article : Google Scholar : PubMed/NCBI
32	Korsisaari N, Ross J, Wu X, et al: Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res. 14:249–258. 2008. View Article : Google Scholar
33	Ortiz LD, Syro LV, Scheithauer BW, et al: Anti-VEGF therapy in pituitary carcinoma. Pituitary. 15:445–449. 2012. View Article : Google Scholar : PubMed/NCBI
34	Jubb AM, Strickland LA, Liu SD, et al: Neuropilin-1 expression in cancer and development. J Pathol. 226:50–60. 2012. View Article : Google Scholar : PubMed/NCBI